Pharma Tech

Kynexis pockets €97m to advance cognition-focused schizophrenia drug

Aug 20, 2026, 10:32 AM

Read Full Article → Kynexis pockets €97m to advance cognition-focused schizophrenia drug

Translate article text

Choose a language and wait for the translated text.

Kynexis will now prepare for registrational studies on lead asset, KYN-5356 in cognitive impairment associated with schizophrenia (CIAS).